| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | August 5, 2024 |
| Accession Number: | 0001193125-24-190811 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/8/2023 | $45.00 | Outperform → Market Perform | TD Cowen |
| 11/20/2023 | $25.00 | Neutral | JP Morgan |
| 9/28/2023 | $33.00 | Overweight | Piper Sandler |
| 8/3/2023 | $36.00 → $31.00 | Buy → Neutral | BofA Securities |
| 5/4/2023 | $30.00 | Equal Weight → Overweight | Wells Fargo |
| 4/10/2023 | Outperform | TD Cowen | |
| 3/17/2023 | $40.00 → $29.00 | Overweight → Neutral | JP Morgan |
| 3/16/2023 | $22.00 | Hold | Berenberg |
15-12G - Cerevel Therapeutics Holdings, Inc. (0001805387) (Filer)
EFFECT - Cerevel Therapeutics Holdings, Inc. (0001805387) (Filer)
EFFECT - Cerevel Therapeutics Holdings, Inc. (0001805387) (Filer)
Cerevel's clinical-stage assets complement AbbVie's emerging neuroscience pipeline and leading on-market brands in psychiatry, migraine and Parkinson's diseaseEmraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophreniaCerevel is a strong strategic fit for AbbVie and has potential to meaningfully impact revenue into the next decadeAbbVie reaffirms previously issued 2024 full-year adjusted diluted EPS guidance range of $10.71-$10.91; reaffirms previously issued third-quarter adjusted diluted EPS guidance range of $2.92-$2.96NORTH CHICAGO, Ill., Aug. 1, 2024 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that it
NEW YORK, May 17, 2024 (GLOBE NEWSWIRE) -- If you invested in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/cerevel-therapeutics-holdings-inc-investigation or contacting us below. Claim Details: On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie. Under the terms of the transaction, AbbVie will acquire all outstanding shares of Cerevel for $45.00 per share in cash. The transaction values Cerevel at a total equity value of approximately $8.7 billion. The boards of directors of both companies have approved the transaction. This transaction is expected to clo
Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-3 adjunctive trial, demonstrating a statistically significant increase in total "on" time without troublesome dyskinesia compared with placebo over 27 weeks Results demonstrate tavapadon's potential to provide the right balance of motor control, safety and tolerability for people living with Parkinson's disease Additional data from the trial will be presented at a future medical meeting; results from the tavapadon Phase 3 monotherapy trials (TEMPO-1 and TEMPO-2) are expected in the second half of 2024 CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unrav